

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1993 Session of
2024

INTRODUCED BY BENHAM, GAYDOS, KENYATTA, BURGOS, HARKINS,
DONAHUE, MADDEN, MAJOR, SANCHEZ, CERRATO, HILL-EVANS,
D'ORSIE, CIRESI, DALEY, MATZIE, SOLOMON, MIHALEK, ECKER,
McNEILL, SCHLOSSBERG, PICKETT, PISCIOTTANO, WEBSTER,
HOHENSTEIN, KRUEGER, BOROWSKI, NEILSON, FEE, KIM, KHAN,
BERNSTINE, MENTZER, O'MARA, FLEMING, GROVE, MULLINS,
KOSIEROWSKI, ISAACSON, HEFFLEY, OBERLANDER, ARMANINI,
GREGORY, E. NELSON, STAATS, WAXMAN, STEELE, SALISBURY,
KINKEAD, McANDREW, KAUFFMAN, GIRAL, DELOZIER, FRITZ,
MUSTELLO, POWELL, D. WILLIAMS, HOGAN, CAUSER, FRIEL, SIEGEL,
WARNER, COOPER, SAMUELSON, KRAJEWSKI, SHUSTERMAN, FRANKEL,
KRUPA, MADSEN, ABNEY, BRIGGS, HANBIDGE, ROZZI, KAZEEM AND
GREEN, APRIL 3, 2024

SENATOR MARTIN, APPROPRIATIONS, IN SENATE, RE-REPORTED AS
AMENDED, JULY 10, 2024

AN ACT

1 ~~Amending the act of November 21, 2016 (P.L.1318, No.169),~~ <--
2 ~~entitled "An act providing for pharmacy audit procedures, for~~
3 ~~registration of pharmacy benefits managers and auditing~~
4 ~~entities, for maximum allowable cost transparency and for~~
5 ~~prescription drugs reimbursed under the PACE and PACENET~~
6 ~~program; and making related repeals," further providing for~~
7 ~~title of act; in preliminary provisions, further providing~~
8 ~~for short title and for definitions; in pharmacy audits,~~
9 ~~further providing for limitations; and providing for pharmacy~~
10 ~~benefits manager contract requirements and prohibited acts.~~
11 AMENDING THE ACT OF NOVEMBER 21, 2016 (P.L.1318, NO.169), <--
12 ENTITLED "AN ACT PROVIDING FOR PHARMACY AUDIT PROCEDURES, FOR
13 REGISTRATION OF PHARMACY BENEFITS MANAGERS AND AUDITING
14 ENTITIES, FOR MAXIMUM ALLOWABLE COST TRANSPARENCY AND FOR
15 PRESCRIPTION DRUGS REIMBURSED UNDER THE PACE AND PACENET
16 PROGRAM; AND MAKING RELATED REPEALS," FURTHER PROVIDING FOR
17 TITLE OF ACT; IN PRELIMINARY PROVISIONS, FURTHER PROVIDING
18 FOR SHORT TITLE, FOR SCOPE OF ACT AND FOR DEFINITIONS AND
19 PROVIDING FOR REGULATIONS; IN PHARMACY AUDITS, FURTHER
20 PROVIDING FOR LIMITATIONS; IN REGISTRATION, FURTHER PROVIDING

1 FOR PBM AND AUDITING ENTITY REGISTRATION; PROVIDING FOR
2 PHARMACY BENEFITS MANAGER CONTRACTS; IN PBM COST TRANSPARENCY
3 REQUIREMENTS, PROVIDING FOR PBM TRANSPARENCY REPORT REQUIRED,
4 REPEALING PROVISIONS RELATING TO REGULATIONS AND PROVIDING
5 FOR PSAO REPORTING REQUIREMENTS; IN ENFORCEMENTS, FURTHER
6 PROVIDING FOR SCOPE OF ENFORCEMENT AUTHORITY; PROVIDING FOR
7 PHARMACY SERVICES; AND MAKING REPEALS.

8 The General Assembly of the Commonwealth of Pennsylvania
9 hereby enacts as follows:

10 ~~Section 1. The title and section 101 of the act of November <--~~
11 ~~21, 2016 (P.L.1318, No.169), known as the Pharmacy Audit~~
12 ~~Integrity and Transparency Act, are amended to read:~~

13 ~~AN ACT~~

14 ~~Providing for pharmacy audit procedures, for registration of~~
15 ~~pharmacy benefits managers and auditing entities, for maximum~~
16 ~~allowable cost transparency and for prescription drugs~~
17 ~~reimbursed under the PACE and PACENET program and for~~
18 ~~pharmacy benefit managers contract requirements and~~
19 ~~prohibited activities; and making related repeals.~~

20 ~~Section 101. Short title.~~

21 ~~This act shall be known and may be cited as the [Pharmacy~~
22 ~~Audit Integrity and Transparency] Community Pharmacy Protection~~
23 ~~Act.~~

24 ~~Section 2. Section 103 of the act is amended by adding~~
25 ~~definitions to read:~~

26 ~~Section 103. Definitions.~~

27 ~~The following words and phrases when used in this act shall~~
28 ~~have the meanings given to them in this section unless the~~
29 ~~context clearly indicates otherwise:~~

30 ~~* * *~~

31 ~~"Brand effective rate." The reimbursement rate paid to the~~
32 ~~pharmacy based on a percentage of the average wholesale cost for~~
33 ~~brand name drugs dispensed by the pharmacy under the contract~~

1 ~~with the pharmacy benefit manager.~~

2 * * *

3 ~~"Effective rate contract." A contract that sets a specific~~
4 ~~discount rate for all prescriptions filled by a member pharmacy~~
5 ~~during the term of the contract.~~

6 * * *

7 ~~"Generic effective rate." The reimbursement rate paid to the~~
8 ~~pharmacy based on a percentage of the average wholesale cost for~~
9 ~~generic drugs dispensed by the pharmacy under the contract with~~
10 ~~the pharmacy benefit manager.~~

11 * * *

12 ~~"Patient steering." One of the following:~~

13 ~~(1) When a pharmacy benefit manager directs a patient to~~
14 ~~use a preferred pharmacy through mandatory mail order~~
15 ~~requirements or the creation by the PBM of a restricted~~
16 ~~network that consists only of pharmacies approved by the PBM.~~

17 ~~(2) The use of co-pay differentials between PBM-~~
18 ~~affiliated pharmacies and nonaffiliated pharmacies.~~

19 * * *

20 ~~"Spread pricing." An act of a pharmacy benefit manager~~
21 ~~reimbursing a pharmacy for a prescription and then billing an~~
22 ~~insurer or an employer that provides health insurance at a~~
23 ~~higher price for the same prescription.~~

24 Section 3. Section 303 of the act is amended by adding a
25 subsection to read:

26 Section 303. Limitations.

27 * * *

28 ~~(c) Scrivener error. A scrivener error made by a pharmacy~~
29 ~~not attributed to fraud, waste or abuse that is discovered~~
30 ~~during an audit of the pharmacy by the PBM shall result in the~~

1 ~~PBM recouping the dispensing fee for that particular~~
2 ~~transaction, not the entire amount of the medication received by~~
3 ~~the patient.~~

4 Section 4. ~~The act is amended by adding a chapter to read:~~

5 ~~CHAPTER 6~~
6 ~~PHARMACY BENEFITS MANAGER CONTRACT~~
7 ~~REQUIREMENTS AND PROHIBITED ACTS~~

8 ~~Section 601. Contract provisions.~~

9 ~~A contract between a pharmacy benefit manager or a designee~~
10 ~~of the pharmacy benefit manager and a pharmacy may not:~~

11 ~~(1) Require participation in the PBM's network~~
12 ~~contingent on the pharmacy signing either an effective rate~~
13 ~~contract or a contract based on the National Average Drug~~
14 ~~Acquisition Cost guidelines.~~

15 ~~(2) Include provisions allowing for retroactive~~
16 ~~recoupment of money paid to a pharmacy by the PBM, unless~~
17 ~~both parties agree to that provision.~~

18 ~~(3) Base reimbursement upon general effective rate or~~
19 ~~the brand effective rate as a condition of entering a~~
20 ~~network, unless both parties agree to that provision. Any~~
21 ~~additional fees must be disclosed and applied at the time of~~
22 ~~the adjudication of the claim. Fees may include:~~

23 ~~(i) Transaction fees.~~

24 ~~(ii) Chargebacks due to recalculation of the cost of~~
25 ~~the ingredients used in a prescription drug.~~

26 ~~(iii) Adjustments in the general effective rate,~~
27 ~~brand effective rates or direct and indirect remuneration~~
28 ~~fees made by the PBM.~~

29 ~~Section 602. Spread pricing participation prohibited.~~

30 ~~A pharmacy benefit manager may not conduct or participate in~~

1 ~~spread pricing.~~

2 ~~Section 603. Patient steering prohibited.~~

3 ~~A pharmacy benefit manager may not conduct or participate in~~
4 ~~patient steering.~~

5 ~~Section 604. Duties of the department.~~

6 ~~The department shall:~~

7 ~~(1) Develop a process for receiving, hearing and~~
8 ~~resolving complaints a pharmacy filed against a PBM.~~

9 ~~(2) Have the ability to set fixed amounts for PBM claim~~
10 ~~processing fees and administrative fees.~~

11 ~~(3) Develop a Statewide National Average Drug~~
12 ~~Acquisition Cost guideline that uses wholesale pricing based~~
13 ~~on manufacturer's invoices of those manufacturers who ship~~
14 ~~drugs to this Commonwealth.~~

15 ~~Section 605. Duties of pharmacy benefit managers.~~

16 ~~Pharmacy benefit managers shall:~~

17 ~~(1) Approve a request from a pharmacy to be a member of~~
18 ~~the PBM's network within 30 days of the initial request to~~
19 ~~join the network.~~

20 ~~(2) Provide a dedicated telephone number and email~~
21 ~~address for handling network admission requests.~~

22 ~~Section 606. PBM for State Employee Health Plan.~~

23 ~~A PBM hired for the State Employee Health Plan shall have a~~
24 ~~transparent reimbursement methodology based on the National~~
25 ~~Average Drug Acquisition Cost guidelines developed under~~
26 ~~section 604(3) and a dispensing fee equal to or greater than the~~
27 ~~maximum prevailing fee for service or PACE rate in this~~
28 ~~Commonwealth.~~

29 ~~Section 607. Reports by PBM.~~

30 ~~A PBM shall report to the department the amount of rebates~~

1 ~~and payments received from drug manufacturers and how the~~
2 ~~rebates and payments were distributed by the PBM.~~

3 ~~Section 5. This act shall take effect in 60 days.~~

4 SECTION 1. THE TITLE AND SECTIONS 101 AND 102 OF THE ACT OF <--
5 NOVEMBER 21, 2016 (P.L.1318, NO.169), KNOWN AS THE PHARMACY
6 AUDIT INTEGRITY AND TRANSPARENCY ACT, ARE AMENDED TO READ:

7 AN ACT
8 PROVIDING FOR PHARMACY AUDIT PROCEDURES, FOR REGISTRATION OF
9 PHARMACY BENEFITS MANAGERS AND AUDITING ENTITIES, FOR MAXIMUM
10 ALLOWABLE COST TRANSPARENCY [AND], FOR PRESCRIPTION DRUGS
11 REIMBURSED UNDER THE PACE AND PACENET PROGRAM AND FOR
12 PHARMACY BENEFIT MANAGERS CONTRACT REQUIREMENTS AND
13 PROHIBITED ACTIVITIES; AND MAKING RELATED REPEALS

14 SECTION 101. SHORT TITLE.

15 THIS ACT SHALL BE KNOWN AND MAY BE CITED AS THE [PHARMACY
16 AUDIT INTEGRITY AND TRANSPARENCY] PHARMACY BENEFIT REFORM ACT.

17 SECTION 102. SCOPE OF ACT.

18 THE FOLLOWING APPLY:

19 (1) THIS ACT COVERS ANY AUDIT OF THE RECORDS OF A
20 PHARMACY CONDUCTED BY A MANAGED CARE COMPANY, THIRD-PARTY
21 PAYER, PHARMACY BENEFITS MANAGER OR AN ENTITY THAT REPRESENTS
22 A COVERED ENTITY.

23 (2) THIS ACT COVERS ANY CONTRACT BETWEEN A PHARMACY OR A
24 PBM AND A HEALTH INSURER OR A HEALTH BENEFIT PLAN, OR A
25 CONTRACT BETWEEN A PHARMACY AND A PBM ON BEHALF OF A HEALTH
26 INSURER OR HEALTH BENEFIT PLAN.

27 (3) EXCEPT FOR THE PROVISIONS OF CHAPTER 5, THIS ACT
28 SHALL NOT APPLY TO A SELF-INSURED HEALTH BENEFIT PLAN SUBJECT
29 TO ERISA OR EXEMPTED FROM ERISA UNDER SECTION 4(B) OF ERISA.

30 SECTION 2. THE DEFINITIONS OF "COVERED ENTITY" AND "HEALTH

1 INSURANCE POLICY" IN SECTION 103 OF THE ACT ARE AMENDED AND THE
2 SECTION IS AMENDED BY ADDING DEFINITIONS TO READ:
3 SECTION 103. DEFINITIONS.

4 THE FOLLOWING WORDS AND PHRASES WHEN USED IN THIS ACT SHALL
5 HAVE THE MEANINGS GIVEN TO THEM IN THIS SECTION UNLESS THE
6 CONTEXT CLEARLY INDICATES OTHERWISE:

7 "AFFILIATE" OR "AFFILIATED." AN "AFFILIATE" AS DEFINED IN
8 SECTION 1401 OF THE ACT OF MAY 17, 1921 (P.L.682, NO.284), KNOWN
9 AS THE INSURANCE COMPANY LAW OF 1921.

10 * * *

11 "COMPLEX OR CHRONIC MEDICAL CONDITION." A PHYSICAL
12 BEHAVIORAL OR DEVELOPMENTAL CONDITION THAT HAS NO KNOWN CURE, IS
13 PROGRESSIVE OR CAN BE DEBILITATING OR FATAL IF UNMANAGED OR
14 UNTREATED.

15 "COVERED ENTITY." A CONTRACT HOLDER OR POLICY HOLDER
16 PROVIDING PHARMACY BENEFITS TO A COVERED INDIVIDUAL UNDER A
17 HEALTH [INSURANCE POLICY] BENEFIT PLAN PURSUANT TO A CONTRACT
18 ADMINISTERED BY A PHARMACY BENEFIT MANAGER.

19 * * *

20 "ERISA." THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974
21 (PUBLIC LAW 93-406, 29 U.S.C. § 1001 ET SEQ.).

22 * * *

23 "HEALTH BENEFIT PLAN." A POLICY, CONTRACT OR CERTIFICATE
24 ENTERED INTO, OFFERED, ISSUED OR RENEWED BY A HEALTH INSURER TO
25 PROVIDE, DELIVER, ARRANGE FOR, PAY FOR OR REIMBURSE ANY OF THE
26 COSTS OF PHYSICAL, MENTAL OR BEHAVIORAL HEALTH CARE SERVICES.
27 THE TERM DOES NOT INCLUDE MEDICARE SUPPLEMENT OR ACCIDENT ONLY,
28 FIXED INDEMNITY, LIMITED BENEFIT, CREDIT, DENTAL, VISION,
29 SPECIFIED DISEASE, TRICARE SUPPLEMENTAL INSURANCE, LONG-TERM
30 CARE OR DISABILITY INCOME, WORKERS' COMPENSATION OR AUTOMOBILE

1 MEDICAL PAYMENT INSURANCE.

2 * * *

3 ["HEALTH INSURANCE POLICY." A POLICY, SUBSCRIBER CONTRACT,
4 CERTIFICATE OR PLAN THAT PROVIDES PRESCRIPTION DRUG COVERAGE.
5 THE TERM INCLUDES BOTH COMPREHENSIVE AND LIMITED BENEFIT HEALTH
6 POLICIES.]

7 * * *

8 "HEALTH INSURER CLIENT." THE TERM INCLUDES BOTH A HEALTH
9 INSURER AND A HEALTH BENEFIT PLAN OFFERED BY A HEALTH INSURER.

10 "LICENSEE OR REGISTRANT." AN ENTITY SUBJECT TO OVERSIGHT OF
11 THE DEPARTMENT UNDER THIS ACT. THE TERM INCLUDES:

12 (1) AN AUDITING ENTITY.

13 (2) A HEALTH INSURER.

14 (3) A PHARMACY BENEFIT MANAGER.

15 (4) A PHARMACY SERVICES ADMINISTRATION ORGANIZATION.

16 "MAIL ORDER PHARMACY." A PHARMACY WHERE PRESCRIPTIONS ARE
17 DISPENSED TO COVERED INDIVIDUALS VIA THE MAIL.

18 "MAINTENANCE MEDICATION." A MEDICATION PRESCRIBED FOR A
19 CHRONIC, LONG-TERM CONDITION AND TAKEN ON A REGULAR, RECURRING
20 BASIS.

21 * * *

22 "RARE MEDICAL CONDITION." A DISEASE OR CONDITION THAT
23 AFFECTS FEWER THAN 200,000 INDIVIDUALS IN THE UNITED STATES OR
24 APPROXIMATELY 1 IN 1,500 INDIVIDUALS WORLDWIDE.

25 "RETAIL PHARMACY." A PHARMACY WHERE PRESCRIPTIONS ARE ABLE
26 TO BE DISPENSED TO COVERED INDIVIDUALS ON THE PREMISES OF THE
27 PHARMACY.

28 * * *

29 "SPECIALTY DRUG." EITHER OF THE FOLLOWING:

30 (1) A PRESCRIPTION DRUG PRESCRIBED TO A COVERED

1 INDIVIDUAL WITH A COST THAT MEETS OR EXCEEDS THE COST OF A
2 DRUG ON THE SPECIALTY TIER OF MEDICARE PART D UNDER 42 CFR
3 423.104(D) (2) (IV) (RELATING TO REQUIREMENTS RELATED TO
4 QUALIFIED PRESCRIPTION DRUG COVERAGE) AND MEETS THREE OR MORE
5 OF THE FOLLOWING CRITERIA:

6 (I) THE DRUG REQUIRES SPECIALIZED PRODUCT HANDLING
7 OR ADMINISTRATION BY THE DISPENSING PHARMACY.

8 (II) THE DRUG REQUIRES SPECIALIZED CLINICAL CARE,
9 INCLUDING, BUT NOT LIMITED TO, FREQUENT DOSING
10 ADJUSTMENTS TO THE PRESCRIPTION DRUG, CLINICAL MONITORING
11 OR EXPANDED PATIENT SERVICE, INTENSIVE PATIENT COUNSELING
12 AND ONGOING CLINICAL SUPPORT, SUCH AS INDIVIDUALIZED
13 DISEASE OR THERAPY MANAGEMENT TO SUPPORT PATIENT OUTCOMES
14 FOR A COVERED INDIVIDUAL.

15 (III) THE DRUG IS PRESCRIBED FOR A COVERED
16 INDIVIDUAL WITH A RARE MEDICAL CONDITION, COMPLEX OR
17 CHRONIC MEDICAL CONDITION OR LIFE-THREATENING MEDICAL
18 CONDITION.

19 (IV) THE PRESCRIPTION DRUG HAS A LIMITED OR
20 EXCLUSIVE DISTRIBUTION AND IS NOT TYPICALLY STOCKED OR
21 DISPENSED BY A RETAIL PHARMACY.

22 (2) A PRESCRIPTION DRUG THAT IS PRESCRIBED TO A COVERED
23 INDIVIDUAL AND THAT IS LISTED AS A SPECIALTY DRUG ON THE
24 MEDICAL ASSISTANCE FEE-FOR-SERVICE SPECIALTY PHARMACY DRUG
25 LIST.

26 "SPECIALTY PHARMACY." A PHARMACY THAT HAS BEEN NATIONALLY
27 ACCREDITED BY AN INDEPENDENT THIRD PARTY TO DISPENSE SPECIALTY
28 DRUGS.

29 "SPREAD PRICING." A MODEL OF PRESCRIPTION DRUG PRICING IN
30 WHICH THE PBM CHARGES A HEALTH BENEFIT PLAN OR HEALTH INSURER A

1 CONTRACTED PRICE FOR PRESCRIPTION DRUGS AND THE CONTRACTED PRICE
2 FOR THE PRESCRIPTION DRUGS DIFFERS FROM THE AMOUNT THE PBM
3 DIRECTLY OR INDIRECTLY PAYS THE PHARMACIST OR PHARMACY FOR
4 PRESCRIPTION DRUGS AND RELATED PHARMACIST SERVICES.

5 SECTION 3. THE ACT IS AMENDED BY ADDING A SECTION TO READ:
6 SECTION 104. REGULATIONS.

7 EXCEPT AS PROVIDED FOR IN CHAPTER 10, THE DEPARTMENT MAY
8 PROMULGATE REGULATIONS NECESSARY FOR THE ADMINISTRATION OF THIS
9 ACT.

10 SECTION 4. SECTION 303 OF THE ACT IS AMENDED BY ADDING A
11 SUBSECTION TO READ:

12 SECTION 303. LIMITATIONS.

13 * * *

14 (C) SCRIVENER'S ERROR.--A SCRIVENER'S ERROR MADE BY A
15 PHARMACY NOT ATTRIBUTED TO FRAUD, WASTE OR ABUSE THAT IS
16 DISCOVERED DURING A PHARMACY AUDIT BY THE PBM SHALL RESULT IN
17 THE PBM RECOUPING THE DISPENSING FEE FOR THAT PARTICULAR
18 TRANSACTION, NOT THE ENTIRE AMOUNT FOR THE MEDICATION RECEIVED
19 BY THE PATIENT.

20 SECTION 5. SECTION 501(B) OF THE ACT IS AMENDED AND THE
21 SECTION IS AMENDED BY ADDING A SUBSECTION TO READ:
22 SECTION 501. PBM AND AUDITING ENTITY REGISTRATION.

23 * * *

24 (A.1) PSAO REGISTRATION.--TO CONDUCT BUSINESS IN THIS
25 COMMONWEALTH, A PSAO SHALL REGISTER WITH THE DEPARTMENT ON AN
26 APPLICATION FORM PROVIDED BY THE DEPARTMENT. THE FORM SHALL
27 REFLECT THE REPORTING REQUIREMENTS UNDER SECTION ~~705~~ 704.1. <--
28 NOTHING UNDER THIS SUBSECTION SHALL BE CONSTRUED AS REQUIRING A
29 HEALTH INSURER, HEALTH BENEFIT PLAN OR PBM TO ENTER INTO A
30 CONTRACT WITH A PSAO.

1 (B) TERM AND FEE.--

2 (1) THE TERM OF REGISTRATION SHALL BE TWO YEARS FROM THE
3 DATE OF ISSUANCE.

4 (2) THE DEPARTMENT SHALL SET AN INITIAL APPLICATION FEE
5 AND A RENEWAL APPLICATION FEE, WHICH SHALL BE SUBMITTED WITH
6 AN APPLICATION FOR REGISTRATION. AN INITIAL APPLICATION FEE
7 SHALL BE NONREFUNDABLE. A RENEWAL APPLICATION FEE SHALL BE
8 RETURNED IF THE RENEWAL OF THE REGISTRATION IS NOT GRANTED.

9 (3) THE AMOUNT OF THE INITIAL APPLICATION FEE AND
10 RENEWAL APPLICATION FEE SHALL BE SUFFICIENT TO FUND THE
11 DEPARTMENT'S DUTIES IN RELATION TO ITS RESPONSIBILITIES UNDER
12 THIS CHAPTER BUT MAY NOT EXCEED [\$1,000.]:

13 (I) \$10,000 FOR A PBM OR AUDITING ENTITY.

14 (II) \$500 FOR A PSAO.

15 * * *

16 SECTION 6. THE ACT IS AMENDED BY ADDING A CHAPTER TO READ:

17 CHAPTER 6

18 PHARMACY BENEFITS MANAGER CONTRACTS

19 SECTION 601. CONTRACT PROVISIONS.

20 (A) GENERAL RULE.--A PBM REGISTERED WITH THE DEPARTMENT AND
21 CONDUCTING BUSINESS ON BEHALF OF A HEALTH INSURER CLIENT IN THIS
22 COMMONWEALTH MAY NOT:

23 (1) REIMBURSE A RETAIL PHARMACY AN AMOUNT LESS THAN THE
24 AMOUNT THAT THE PBM REIMBURSES A PBM-AFFILIATED RETAIL
25 PHARMACY LOCATED IN THIS COMMONWEALTH FOR PROVIDING THE SAME
26 PHARMACIST SERVICES.

27 (2) REIMBURSE A FEDERALLY QUALIFIED HEALTH CENTER,
28 HEALTH CARE FACILITY OR OTHER ENTITY PARTICIPATING IN THE
29 PROGRAM UNDER SECTION 340(B) OF THE PUBLIC HEALTH SERVICE ACT
30 (58 STAT. 682, 42 U.S.C. § 256(B)), AN AMOUNT LESSER THAN

1 SIMILAR ENTITIES NOT PARTICIPATING IN THE PROGRAM.

2 (3) AUTHORIZE THE PBM TO UNILATERALLY ALTER THE TERMS OF
3 A PARTICIPATION CONTRACT BEYOND THE TERMS AND CONDITIONS OF
4 THE ORIGINAL CONTRACT AGREED TO BY A PSAO OR PHARMACY WITH A
5 PBM BEYOND THE TERMS AND CONDITIONS OF THE ORIGINAL CONTRACT
6 AGREED TO BY THE PHARMACY OR PSAO WITH A PBM.

7 (4) DESIGNATE A PRESCRIPTION DRUG AS A SPECIALTY DRUG OR
8 REQUIRE A PRESCRIPTION DRUG TO BE DISPENSED EXCLUSIVELY AT A
9 SPECIALTY PHARMACY UNLESS IT MEETS THE CRITERIA OF A
10 SPECIALTY DRUG UNDER SECTION 103.

11 (B) REBATES.--BEGINNING ON THE EFFECTIVE DATE OF THIS
12 SECTION, A PBM SHALL PASS THROUGH TO THE HEALTH BENEFIT PLAN NO
13 LESS THAN 95% OF ANY PRESCRIPTION DRUG MANUFACTURER REBATE
14 OBTAINED BY THE PBM ON BEHALF OF A HEALTH INSURER CLIENT IF THE
15 HEALTH BENEFIT PLAN DELEGATES NEGOTIATION OF THE REBATE TO THE
16 PBM.

17 (C) CONTRACT INFORMATION.--PBM CONTRACTS SHALL PROVIDE
18 INFORMATION TO A PHARMACIST, PHARMACY OR PSAO PERTAINING TO THE
19 SCHEDULE AND TOTAL FOR ANY FEE CHARGED BY THE PBM FOR
20 PARTICIPATION IN THE PBM'S NETWORK.

21 SECTION 602. PATIENT STEERING.

22 (A) PROHIBITIONS.--A HEALTH BENEFIT PLAN, HEALTH INSURER OR
23 PBM CONTRACTING WITH A HEALTH BENEFIT PLAN OR HEALTH INSURER MAY
24 NOT:

25 (1) REQUIRE A COVERED INDIVIDUAL, AS A CONDITION OF
26 PAYMENT OR REIMBURSEMENT, TO PURCHASE PHARMACIST SERVICES,
27 INCLUDING, BUT NOT LIMITED TO, PRESCRIPTION DRUGS,
28 EXCLUSIVELY THROUGH A MAIL-ORDER PHARMACY OR PBM RETAIL
29 PHARMACY AFFILIATE.

30 (2) PROHIBIT OR LIMIT A COVERED INDIVIDUAL FROM

<--

1 SELECTING AN IN-NETWORK PHARMACY OR IN-NETWORK PHARMACIST OF
2 THE COVERED INDIVIDUAL'S CHOICE IF THAT PHARMACY OR
3 PHARMACIST MEETS AND AGREES TO THE TERMS AND CONDITIONS,
4 INCLUDING REIMBURSEMENTS, IN THE PBM'S CONTRACT.

5 (3) REQUIRE A COVERED INDIVIDUAL TO USE A PBM-AFFILIATED
6 RETAIL PHARMACY.

7 (4) TRANSFER A COVERED INDIVIDUAL'S PRESCRIPTIONS FROM
8 AN IN-NETWORK PHARMACY TO ANOTHER PHARMACY UNLESS REQUESTED
9 BY THE COVERED INDIVIDUAL.

10 (5) USE FINANCIAL INCENTIVES, INCLUDING, BUT NOT LIMITED
11 TO, ADJUSTMENTS IN COST SHARING OBLIGATIONS OF A COVERED
12 INDIVIDUAL, TO THE EXCLUSIVE BENEFIT OF A PBM-AFFILIATED
13 RETAIL PHARMACY.

14 (6) EXCEPT AS PROVIDED IN SUBSECTION (B), AUTO-ENROLL A
15 COVERED INDIVIDUAL IN MAIL-ORDER PHARMACY SERVICES.

16 (B) CONSTRUCTION.--NOTHING IN THIS SECTION SHALL BE
17 CONSTRUED:

18 (1) TO PREVENT A PBM, HEALTH BENEFIT PLAN OR HEALTH
19 INSURER FROM REQUIRING A COVERED INDIVIDUAL TO USE AN
20 APPROVED SPECIALTY PHARMACY OPERATING IN THE PBM'S NETWORK.

21 (2) TO PREVENT A HEALTH BENEFIT PLAN, HEALTH INSURER OR
22 PBM CONTRACTING WITH A HEALTH BENEFIT PLAN OR HEALTH INSURER,
23 FROM AUTO-ENROLLING A COVERED INDIVIDUAL IN MAIL-ORDER
24 SERVICES FOR A MAINTENANCE MEDICATION, PROVIDED THAT:

25 (I) A COVERED INDIVIDUAL MAY NOT BE AUTO-ENROLLED
26 FOR THE FIRST 90 DAYS OF A NEW MAINTENANCE MEDICATION;
27 AND

28 (II) A COVERED INDIVIDUAL SHALL HAVE THE ABILITY TO
29 OPT OUT OF MAIL-ORDER PHARMACY SERVICES AT ANY TIME.

30 SECTION 603. CLAWBACKS PROHIBITED.

1 (A) GENERAL RULE.--A PHARMACIST, PHARMACY INTERN OR
2 TECHNICIAN MAY NOT CHARGE A PATIENT AN AMOUNT FOR A COVERED
3 PRESCRIPTION DRUG THAT EXCEEDS THE LESSER OF:

4 (1) THE NET REIMBURSEMENT PAID TO THE PHARMACY FOR THE
5 PRESCRIPTION DRUG BY THE HEALTH BENEFIT PLAN, HEALTH INSURER
6 OR PBM CONTRACTING WITH A HEALTH BENEFIT PLAN OR HEALTH
7 INSURER.

8 (2) THE AMOUNT AN INDIVIDUAL WOULD PAY FOR THE
9 PRESCRIPTION DRUG IF THE PRESCRIPTION DRUG WERE PURCHASED
10 WITHOUT COVERAGE UNDER A HEALTH BENEFIT PLAN.

11 (B) COLLECTION OF DIFFERENCE IN COST SHARING.--A HEALTH
12 BENEFIT PLAN, HEALTH INSURER OR PBM CONTRACTING WITH A HEALTH
13 BENEFIT PLAN OR HEALTH INSURER MAY NOT COLLECT FROM THE MEMBER
14 ANY DIFFERENCE IN COST SHARING THE MEMBER PAYS TO THE PHARMACY
15 AND THE MEMBER'S COST SHARING DEFINED IN THE MEMBER'S BENEFIT
16 PLAN.

17 SECTION 604. NETWORK ADEQUACY.

18 (A) GENERAL RULE.--A PBM SHALL ESTABLISH A REASONABLY
19 ADEQUATE AND ACCESSIBLE RETAIL PHARMACY NETWORK FOR THE
20 PROVISION OF PRESCRIPTION DRUGS UNDER A HEALTH BENEFIT PLAN THAT
21 SHALL PROVIDE FOR CONVENIENT PATIENT ACCESS TO PHARMACIES WITHIN
22 A REASONABLE DISTANCE FROM A PATIENT'S RESIDENCE IN ACCORDANCE
23 WITH THE FOLLOWING REQUIREMENTS:

24 (1) THE NETWORK MAY NOT BE LIMITED TO AFFILIATED
25 PHARMACIES ONLY.

26 (2) THE NETWORK SHALL MEET OR EXCEED THE REQUIREMENTS OF
27 42 CFR 423.120(A) (RELATING TO ACCESS TO COVERED PART D DRUGS)
28 OR A SUCCESSOR REGULATION. IF A PBM FAILS TO COMPLY WITH THE
29 REQUIREMENTS, IT SHALL NOT BE CONSIDERED A VIOLATION IF THE
30 PBM CONTRACTS WITH ALL RETAIL PHARMACIES WITHIN THE NETWORK

1 DISTANCE STANDARDS OF THE HEALTH BENEFIT PLAN PARTICIPANTS.
2 (B) REPORT REQUIREMENT.--BEGINNING APRIL 1, 2026, AND
3 ANNUALLY THEREAFTER, A PBM SHALL FILE WITH THE DEPARTMENT A
4 NETWORK ADEQUACY REPORT, ON A FORM PRESCRIBED BY THE DEPARTMENT,
5 DESCRIBING THE PBM NETWORK AND THE PBM NETWORK'S ACCESSIBILITY
6 IN THIS COMMONWEALTH. THE REPORTS SHALL BE POSTED ON THE
7 DEPARTMENT'S PUBLICLY ACCESSIBLE INTERNET WEBSITE.

8 SECTION 7. THE ACT IS AMENDED BY ADDING A SECTION TO READ:
9 SECTION 703.1. PBM TRANSPARENCY REPORT REQUIRED.

10 (A) GENERAL RULE.--BEGINNING JULY 1, 2026, AND ANNUALLY
11 THEREAFTER, EACH REGISTERED PBM SHALL SUBMIT TO THE DEPARTMENT A
12 TRANSPARENCY REPORT CONTAINING DATA FOR EACH HEALTH INSURER
13 CLIENT IN THIS COMMONWEALTH FROM THE PRIOR CALENDAR YEAR. THE
14 TRANSPARENCY REPORT SHALL CONTAIN THE FOLLOWING INFORMATION:

15 (1) THE AGGREGATE AMOUNT OF ALL REBATES THAT THE PBM
16 RECEIVED FROM ALL PHARMACEUTICAL MANUFACTURERS FOR ALL HEALTH
17 INSURER CLIENTS AND FOR EACH HEALTH INSURER CLIENT.

18 (2) THE AGGREGATE ADMINISTRATIVE FEES THAT THE PBM
19 RECEIVED FROM ALL MANUFACTURERS FOR ALL HEALTH INSURER
20 CLIENTS AND FOR EACH HEALTH INSURER CLIENT.

21 (3) THE AGGREGATE-RETAINED REBATES THAT THE PBM RECEIVED
22 FROM ALL PHARMACEUTICAL MANUFACTURERS AND DID NOT PASS
23 THROUGH TO HEALTH INSURER CLIENTS.

24 (4) THE HIGHEST, LOWEST AND MEAN AGGREGATE RETAINED
25 REBATE PERCENTAGE FOR ALL HEALTH INSURER CLIENTS AND FOR EACH
26 HEALTH INSURER CLIENT.

27 (5) FOR A PBM THAT CONTROLS OR IS AFFILIATED WITH A
28 PHARMACY, A DESCRIPTION OF ANY DIFFERENCES BETWEEN WHAT THE
29 PBM REIMBURSES OR CHARGES AFFILIATED AND NONAFFILIATED
30 PHARMACIES.

1 (B) PUBLICATION.--WITHIN 60 DAYS OF RECEIPT, THE DEPARTMENT
2 SHALL PUBLISH THE TRANSPARENCY REPORT UNDER THIS SECTION ON THE
3 DEPARTMENT'S PUBLICLY ACCESSIBLE INTERNET WEBSITE IN A FORM THAT
4 MEETS THE FOLLOWING REQUIREMENTS:

5 (1) DOES NOT DISCLOSE THE NAME OF A PBM.

6 (2) DOES NOT DIRECTLY OR INDIRECTLY DISCLOSE THE
7 IDENTITY OF A SPECIFIC HEALTH INSURER CLIENT OR PRESENT
8 INFORMATION IN A MANNER THAT CAN BE EXTRAPOLATED TO IDENTIFY
9 A SPECIFIC HEALTH INSURER CLIENT.

10 (3) DOES NOT LIST THE PRICE OR PRICES CHARGED FOR A
11 SPECIFIC DRUG OR CLASS OF DRUGS.

12 (4) DOES NOT SPECIFY THE AMOUNT OF ANY REBATES PROVIDED
13 FOR A SPECIFIC DRUG OR CLASS OF DRUG.

14 (C) ADDITIONAL CATEGORIES.--THE DEPARTMENT MAY, BY
15 REGULATION, DIRECT PBMS TO INCLUDE ADDITIONAL CATEGORIES FOR
16 AGGREGATED DATA FROM HEALTH INSURER CLIENTS IN THE ANNUAL
17 TRANSPARENCY REPORT SUBMITTED UNDER THIS SECTION.

18 (D) CONFIDENTIALITY.--

19 (1) THE INFORMATION SUBMITTED TO THE DEPARTMENT IN
20 ACCORDANCE WITH THE TRANSPARENCY REPORT REQUIRED UNDER
21 SUBSECTION (A) SHALL BE PRIVILEGED AND GIVEN CONFIDENTIAL
22 TREATMENT AND SHALL NOT BE:

23 (I) SUBJECT TO DISCOVERY OR ADMISSIBLE AS EVIDENCE
24 IN A PRIVATE CIVIL ACTION;

25 (II) SUBJECT TO SUBPOENA;

26 (III) SUBJECT TO ACCESS UNDER THE ACT OF FEBRUARY
27 14, 2008 (P.L.6, NO.3), KNOWN AS THE RIGHT-TO-KNOW LAW;

28 OR

29 (IV) MADE PUBLIC BY THE DEPARTMENT OR ANY OTHER
30 PERSON WITHOUT THE PRIOR WRITTEN CONSENT OF THE PBM,

1 INSURER OR INSURANCE GROUP TO WHICH IT PERTAINS, EXCEPT
2 AS PROVIDED IN PARAGRAPH (3).

3 (2) THE COMMISSIONER, THE DEPARTMENT, A PERSON WHO
4 RECEIVES INFORMATION UNDER SUBSECTION (A) WHILE ACTING UNDER
5 THE AUTHORITY OF THE COMMISSIONER OR DEPARTMENT OR A PERSON
6 WITH WHOM THE INFORMATION IS SHARED UNDER THIS CHAPTER SHALL
7 NOT BE PERMITTED OR REQUIRED TO TESTIFY IN A PRIVATE CIVIL
8 ACTION CONCERNING CONFIDENTIAL INFORMATION IN THE
9 TRANSPARENCY REPORT.

10 (3) TO ASSIST IN THE PERFORMANCE OF ITS REGULATORY
11 DUTIES, THE DEPARTMENT MAY:

12 (I) USE INFORMATION SUBMITTED UNDER THIS SECTION IN
13 FURTHERANCE OF A REGULATORY OR LEGAL ACTION BROUGHT
14 PURSUANT TO THE DEPARTMENT'S OFFICIAL DUTIES.

15 (II) SHARE INFORMATION SUBMITTED UNDER THIS SECTION
16 WITH THE NAIC, REGULATORY OR LAW ENFORCEMENT OFFICIALS OF
17 THIS COMMONWEALTH OR OTHER JURISDICTIONS, AND THIRD-PARTY
18 CONSULTANTS, IF, PRIOR TO RECEIVING THE TRANSPARENCY
19 REPORT INFORMATION, THE RECIPIENT DEMONSTRATES BY WRITTEN
20 STATEMENT THE NECESSARY AUTHORITY AND INTENT TO GIVE
21 CONFIDENTIAL TREATMENT TO THE INFORMATION AS REQUIRED BY
22 THIS SECTION.

23 (III) PUBLISH ALL OR PART OF THE INFORMATION IF,
24 AFTER GIVING THE ENTITY WHO WOULD BE AFFECTED THEREBY
25 NOTICE AND OPPORTUNITY TO BE HEARD, THE DEPARTMENT
26 DETERMINES THAT THE INTEREST OF THE PUBLIC WILL BE SERVED
27 BY THE PUBLICATION THEREOF.

28 (4) THE SHARING OF INFORMATION BY THE DEPARTMENT UNDER
29 THIS SECTION DOES NOT CONSTITUTE A DELEGATION OF REGULATORY
30 AUTHORITY OR RULEMAKING. THE DEPARTMENT SHALL BE SOLELY

1 RESPONSIBLE FOR THE ADMINISTRATION, EXECUTION AND ENFORCEMENT
2 OF THIS CHAPTER.

3 (5) THE SHARING OF TRANSPARENCY REPORT INFORMATION WITH,
4 TO OR BY THE DEPARTMENT AS AUTHORIZED BY THIS CHAPTER DOES
5 NOT CONSTITUTE A WAIVER OF ANY APPLICABLE PRIVILEGE OR CLAIM
6 OF CONFIDENTIALITY.

7 (6) INFORMATION SUBMITTED UNDER THIS SECTION THAT IS IN
8 THE POSSESSION OR CONTROL OF THE NAIC OR A THIRD-PARTY
9 CONSULTANT AS PROVIDED UNDER THIS SECTION SHALL:

10 (I) BE CONFIDENTIAL AND PRIVILEGED;

11 (II) BE EXEMPT FROM ACCESS UNDER THE RIGHT-TO-KNOW
12 LAW;

13 (III) NOT BE SUBJECT TO SUBPOENA; AND

14 (IV) NOT BE SUBJECT TO DISCOVERY OR ADMISSIBLE AS
15 EVIDENCE IN A PRIVATE CIVIL ACTION.

16 SECTION 8. SECTION 704 OF THE ACT IS REPEALED:

17 [SECTION 704. REGULATIONS.]

18 THE DEPARTMENT MAY PROMULGATE REGULATIONS AS NECESSARY AND
19 APPROPRIATE TO IMPLEMENT THE PROVISIONS OF THIS CHAPTER.]

20 SECTION 9. THE ACT IS AMENDED BY ADDING A SECTION TO READ:

21 SECTION 704.1. PSAO REPORTING REQUIREMENTS.

22 A PSAO SHALL PROVIDE THE FOLLOWING INFORMATION TO THE
23 DEPARTMENT AND EACH PHARMACY THAT HAS CONTRACTED FOR SERVICES:

24 (1) CHANGES IN THE PSAO'S OWNERSHIP, INCLUDING A PARENT
25 COMPANY OR SUBSIDIARY OF THE PSAO, NO LATER THAN FIVE DAYS
26 PRIOR TO THE CHANGE IN OWNERSHIP OF THE PSAO, THE PARENT
27 COMPANY OF A PSAO OR A SUBSIDIARY OF THE PSAO.

28 (2) WHETHER THE CHANGE IN OWNERSHIP INCLUDES A COMPANY
29 OR ORGANIZATION THAT PROVIDES PHARMACEUTICAL, PRESCRIPTION
30 DRUG OR DEVICE SERVICES.

1 (3) WHETHER THE CHANGE IN OWNERSHIP INCLUDES A COMPANY
2 THAT SELLS OR MANUFACTURERS PRESCRIPTION DRUGS, BIOLOGICS OR
3 MEDICAL DEVICES.

4 SECTION 10. SECTION 901 OF THE ACT IS AMENDED TO READ:

5 SECTION 901. SCOPE OF ENFORCEMENT AUTHORITY.

6 (A) SCOPE.--THE DEPARTMENT MAY INVESTIGATE AND ENFORCE THE
7 PROVISIONS OF THIS ACT ONLY INSOFAR AS THE ACTIONS OR INACTIONS
8 BEING INVESTIGATED RELATE TO PRESCRIPTION DRUG COVERAGE UNDER A
9 HEALTH [INSURANCE POLICY] BENEFIT PLAN.

10 [(B) REMEDY.--ACTIONS OR INACTIONS WITHIN THE SCOPE OF THE
11 DEPARTMENT'S INVESTIGATIVE AND ENFORCEMENT AUTHORITY UNDER
12 SUBSECTION (A) FOUND TO VIOLATE THIS ACT CONSTITUTE "UNFAIR
13 METHODS OF COMPETITION" AND "UNFAIR OR DECEPTIVE ACTS OR
14 PRACTICES" WITHIN THE MEANING OF SECTION 5 OF THE ACT OF JULY
15 22, 1974 (P.L.589, NO.205), KNOWN AS THE UNFAIR INSURANCE
16 PRACTICES ACT. A PROCEEDING UNDER THIS SECTION SHALL BE
17 CONDUCTED IN ACCORDANCE WITH 2 PA.C.S. CH. 5 SUBCH. A (RELATING
18 TO PRACTICE AND PROCEDURE OF COMMONWEALTH AGENCIES).]

19 (B.1) EXAMINATION AND ACCESS TO RECORDS.--THE FOLLOWING
20 APPLY:

21 (1) (I) THE DEPARTMENT MAY ORDER A PBM, A HEALTH
22 INSURER AND A PBM'S AFFILIATES TO PRODUCE RECORDS, BOOKS OR
23 OTHER INFORMATION AS REASONABLY NECESSARY TO ASCERTAIN
24 COMPLIANCE WITH THIS ACT.

25 (II) THE DEPARTMENT MAY RETAIN AN EXPERT OR EXPERTS
26 AS REASONABLY NECESSARY TO ASSIST THE DEPARTMENT TO
27 CONDUCT AN ANALYSIS OF PBM BUSINESS PRACTICES UNDER THIS
28 PARAGRAPH. THE REASONABLE AND NECESSARY COSTS FOR THE
29 EXPERT SERVICES SHALL BE PAID BY THE PBM, PAYABLE WITHIN
30 30 DAYS OF THE PBM'S RECEIPT OF A BILL FOR THE SERVICES.

1 ANALYSIS UNDER THIS SECTION SHALL INCLUDE:

2 (A) THE IMPACT OF STEERING AND SPREAD PRICING ON
3 THE COST OF PRESCRIPTION DRUGS TO CONSUMERS IN THIS
4 COMMONWEALTH AND PHARMACY ACCESS.

5 (B) THE IMPACT TO CONSUMERS AND PHARMACIES IN
6 THIS COMMONWEALTH BY REQUIRING A HEALTH BENEFIT PLAN
7 OR PBM CONTRACTING WITH A HEALTH BENEFIT PLAN TO
8 REIMBURSE A PHARMACY UTILIZING THE NATIONAL AVERAGE
9 DRUG ACQUISITION COST AND A PROFESSIONAL DISPENSING
10 FEE OF \$10.49.

11 (2) THE DEPARTMENT MAY EXAMINE OR AUDIT THE BOOKS AND
12 RECORDS OF A PBM, A HEALTH INSURER AND A PBM'S AFFILIATES TO
13 ASCERTAIN COMPLIANCE WITH THIS ACT. THE EXAMINATION SHALL BE
14 CONDUCTED IN ACCORDANCE WITH ARTICLE IX OF THE ACT OF MAY 17,
15 1921 (P.L.789, NO.285), KNOWN AS THE INSURANCE DEPARTMENT ACT
16 OF 1921.

17 (C) REVIEW OF SPECIALTY DRUGS.--THE DEPARTMENT SHALL
18 ESTABLISH AN EFFICIENT PROCESS BY WHICH A PHARMACY MAY REFER
19 DESIGNATION OF A PRESCRIPTION DRUG UNDER A HEALTH BENEFIT PLAN,
20 BY A PBM CONTRACTING WITH A HEALTH BENEFIT PLAN, OR A HEALTH
21 INSURER AS A SPECIALTY DRUG WHICH FAILS TO MEET THE CRITERIA
22 UNDER SECTION 103. NO LATER THAN 60 DAYS FOLLOWING THE EFFECTIVE
23 DATE OF THIS SUBSECTION, THE DEPARTMENT SHALL PUBLISH GUIDANCE
24 TO EFFECTUATE THIS SUBSECTION, INCLUDING THE LIST OF
25 PRESCRIPTION DRUGS CLASSIFIED AS A SPECIALTY DRUG UNDER THE
26 MEDICAL ASSISTANCE FEE-FOR-SERVICE PROGRAM. THE LIST UNDER THIS
27 SUBSECTION SHALL NOT BE CONSIDERED EXCLUSIVE FOR THE PURPOSES OF
28 REVIEW BY THE DEPARTMENT UNDER THIS SECTION. THE DEPARTMENT
29 SHALL UPDATE GUIDANCE UNDER THIS SECTION TO REFLECT CHANGES IN
30 SPECIALTY DRUGS UNDER THE MEDICAL ASSISTANCE FEE-FOR-SERVICE

1 PROGRAM FOR EACH PLAN YEAR.

2 (D) PENALTIES.--UPON THE DETERMINATION, AFTER NOTICE AND
3 HEARING, THAT THIS ACT HAS BEEN VIOLATED, THE COMMISSIONER MAY
4 IMPOSE THE FOLLOWING PENALTIES:

5 (1) SUSPENSION OR REVOCATION OF THE LICENSEE OR
6 REGISTRANT'S LICENSE, AUTHORIZATION TO OPERATE OR
7 REGISTRATION.

8 (2) REFUSAL TO ISSUE OR RENEW A LICENSE, AUTHORIZATION
9 TO OPERATE OR REGISTRATION.

10 (3) A CEASE AND DESIST ORDER.

11 (4) ORDER REIMBURSEMENT TO AN INSURED, PHARMACY OR
12 DISPENSER THAT HAS INCURRED A MONETARY LOSS AS A RESULT OF A
13 VIOLATION OF THIS ACT.

14 (5) FOR EACH VIOLATION OF THIS ACT THAT A LICENSEE OR
15 REGISTRANT KNEW OR REASONABLY SHOULD HAVE KNOWN WAS A
16 VIOLATION, A PENALTY OF NOT MORE THAN \$100,000, NOT TO EXCEED
17 AN AGGREGATE PENALTY OF \$1,000,000 IN A SINGLE CALENDAR YEAR.

18 (6) FOR EACH VIOLATION OF THIS ACT THAT A LICENSEE OR
19 REGISTRANT DID NOT KNOW NOR REASONABLY SHOULD HAVE KNOWN WAS
20 A VIOLATION, A PENALTY OF NOT MORE THAN \$50,000, NOT TO
21 EXCEED AN AGGREGATE PENALTY OF \$500,000 IN A SINGLE CALENDAR
22 YEAR.

23 (E) ADDITIONAL REMEDIES.--THE ENFORCEMENT REMEDIES IMPOSED
24 UNDER THIS SECTION ARE IN ADDITION TO ANY OTHER REMEDIES OR
25 PENALTIES THAT MAY BE IMPOSED UNDER ANY OTHER APPLICABLE LAW OF
26 THIS COMMONWEALTH, INCLUDING THE ACT OF JULY 22, 1974 (P.L.589,
27 NO.205), KNOWN AS THE UNFAIR INSURANCE PRACTICES ACT. A
28 VIOLATION OF THIS ACT SHALL BE DEEMED TO BE AN UNFAIR METHOD OF
29 COMPETITION AND AN UNFAIR OR DECEPTIVE ACT OR PRACTICE UNDER THE
30 UNFAIR INSURANCE PRACTICES ACT.

1 (F) ADMINISTRATIVE PROCEDURE.--THE ADMINISTRATIVE PROVISIONS
2 OF THIS SECTION SHALL BE SUBJECT TO 2 PA.C.S. CH. 5 SUBCH. A
3 (RELATING TO PRACTICE AND PROCEDURE OF COMMONWEALTH AGENCIES).
4 A PARTY AGAINST WHOM PENALTIES ARE ASSESSED IN AN ADMINISTRATIVE
5 ACTION MAY APPEAL TO COMMONWEALTH COURT AS PROVIDED IN 2 PA.C.S.
6 CH. 7 SUBCH. A (RELATING TO JUDICIAL REVIEW OF COMMONWEALTH
7 AGENCY ACTION).

8 SECTION 11. THE ACT IS AMENDED BY ADDING A CHAPTER TO READ:

9 CHAPTER 10

10 PHARMACY SERVICES

11 SECTION 1001. DEFINITIONS.

12 THE FOLLOWING WORDS AND PHRASES WHEN USED IN THIS CHAPTER
13 SHALL HAVE THE MEANINGS GIVEN TO THEM IN THIS SECTION UNLESS THE
14 CONTEXT CLEARLY INDICATES OTHERWISE:

15 "BOARD." THE STATE BOARD OF PHARMACY.

16 "COVID-19" OR "CORONAVIRUS DISEASE 2019." A HIGHLY
17 CONTAGIOUS INFECTIOUS DISEASE CAUSED BY SEVERE ACUTE RESPIRATORY
18 SYNDROME CORONAVIRUS 2 (SARS-COV-2).

19 "DIRECT AND IMMEDIATE PERSONAL SUPERVISION." AS FOLLOWS:

20 (1) REVIEW BY THE PHARMACIST OF THE PRESCRIPTION OR DRUG
21 ORDER PRIOR TO DISPENSING.

22 (2) VERIFICATION BY THE PHARMACIST OF THE FINAL PRODUCT.

23 (3) IMMEDIATE AVAILABILITY OF THE PHARMACIST ON THE
24 PREMISES TO DIRECT THE WORK OF THE SUPERVISED INDIVIDUAL AND
25 TO RESPOND TO QUESTIONS OR PROBLEMS.

26 "LICENSEE." AN INDIVIDUAL LICENSED BY THE BOARD.

27 "PHARMACY ACT." THE ACT OF SEPTEMBER 27, 1961 (P.L.1700,
28 NO.699), KNOWN AS THE PHARMACY ACT.

29 "PHARMACY TECHNICIAN." AN INDIVIDUAL WHO:

30 (1) IS REQUIRED TO BE REGISTERED WITH THE BOARD AS A

1 PHARMACY TECHNICIAN FOLLOWING THE PROMULGATION OF FINAL-FORM
2 REGULATIONS UNDER SECTION 3 OF THE ACT OF NOVEMBER 30, 2020
3 (P.L.1306, NO.140), ENTITLED "AN ACT AMENDING THE ACT OF
4 SEPTEMBER 27, 1961 (P.L.1700, NO.699), ENTITLED 'AN ACT
5 RELATING TO THE REGULATION OF THE PRACTICE OF PHARMACY,
6 INCLUDING THE SALES, USE AND DISTRIBUTION OF DRUGS AND
7 DEVICES AT RETAIL; AND AMENDING, REVISING, CONSOLIDATING AND
8 REPEALING CERTAIN LAWS RELATING THERETO,' FURTHER PROVIDING
9 FOR DEFINITIONS; AND PROVIDING FOR PHARMACY TECHNICIAN AND
10 PHARMACY TECHNICIAN TRAINEE REGISTRATION, QUALIFICATIONS AND
11 SUPERVISION, FOR PHARMACY TECHNICIAN DATA ENTRY AND FOR
12 LABORATORY WAIVER."

13 (2) MAY ASSIST IN THE PRACTICE OF PHARMACY UNDER THE
14 DIRECT AND IMMEDIATE PERSONAL SUPERVISION OF A LICENSED
15 PHARMACIST AFTER MEETING THE REQUIREMENTS OF THIS ACT, THE
16 PHARMACY ACT AND THE REGULATIONS PROMULGATED UNDER THIS ACT
17 OR THE PHARMACY ACT. THE TERM SHALL NOT INCLUDE AN INDIVIDUAL
18 PERFORMING CLERICAL SUPPORT WITH NO DIRECT INTERACTION WITH
19 PRESCRIPTION MEDICATION OR ABILITY TO ENTER A PRESCRIPTION
20 DRUG ORDER.

21 "PRACTICE OF PHARMACY." THE FOLLOWING:

22 (1) THE PROVISION OF HEALTH CARE SERVICES BY A
23 PHARMACIST, WHICH INCLUDES:

24 (I) THE INTERPRETATION, EVALUATION AND
25 IMPLEMENTATION OF MEDICAL ORDERS FOR THE PROVISION OF
26 PHARMACY SERVICES OR PRESCRIPTION DRUG ORDERS.

27 (II) THE DELIVERY, DISPENSING OR DISTRIBUTION OF
28 PRESCRIPTION DRUGS.

29 (III) PARTICIPATION IN DRUG AND DEVICE SELECTION.

30 (IV) DRUG ADMINISTRATION.

1 (V) DRUG REGIMEN REVIEW.

2 (VI) DRUG THERAPY MANAGEMENT, INCLUDING SUCH
3 SERVICES PROVIDED UNDER THE MEDICARE PRESCRIPTION DRUG,
4 IMPROVEMENTS, AND MODERNIZATION ACT OF 2003 (PUBLIC LAW
5 108-173, 117 STAT. 2066).

6 (VII) DRUG OR DRUG-RELATED RESEARCH.

7 (VIII) COMPOUNDING.

8 (IX) PROPER AND SAFE STORAGE OF DRUGS AND DEVICES.

9 (X) MANAGEMENT OF DRUG THERAPY UNDER SECTION 9.3 OF
10 THE PHARMACY ACT, OR, IF IN AN INSTITUTIONAL SETTING,
11 CONSISTENT WITH THE INSTITUTION'S ASSIGNMENT OF CLINICAL
12 DUTIES PURSUANT TO A WRITTEN AGREEMENT OR PROTOCOL AS
13 SPECIFIED IN SECTION 9.1 OF THE PHARMACY ACT.

14 (XI) MAINTAINING PROPER RECORDS.

15 (XII) PATIENT COUNSELING.

16 (XIII) ACTS, SERVICES, OPERATIONS OR TRANSACTIONS
17 NECESSARY OR INCIDENT TO THE PROVISION OF THESE HEALTH
18 CARE SERVICES.

19 (2) THE TERM SHALL NOT INCLUDE THE OPERATIONS OF A
20 MANUFACTURER OR DISTRIBUTOR AS DEFINED IN THE CONTROLLED
21 SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT.

22 "THE CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT."
23 THE ACT OF APRIL 14, 1972 (P.L.233, NO.64), KNOWN AS THE
24 CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT, OR THE
25 CONTROLLED SUBSTANCES ACT (PUBLIC LAW 91-513, 84 STAT. 1236).
26 SECTION 1002. ADMINISTRATION OF INJECTABLE MEDICATIONS,
27 BIOLOGICALS AND IMMUNIZATIONS.

28 (A) GENERAL RULE.--THE BOARD SHALL BY REGULATION ESTABLISH
29 EDUCATION AND TRAINING STANDARDS AND PRACTICE GUIDELINES
30 PURSUANT TO WHICH PHARMACISTS SHALL BE AUTHORIZED TO ADMINISTER

1 INJECTABLE MEDICATIONS, BIOLOGICALS AND IMMUNIZATIONS TO
2 INDIVIDUALS EIGHT YEARS OF AGE OR OLDER AND INFLUENZA AND COVID-
3 19 IMMUNIZATIONS BY INJECTABLE OR NEEDLE-FREE DELIVERY METHODS
4 TO INDIVIDUALS FIVE YEARS OF AGE OR OLDER. THE STANDARDS AND
5 GUIDELINES SHALL INCLUDE, BUT NOT BE LIMITED TO, THE FOLLOWING:

6 (1) SATISFACTORY COMPLETION OF AN ACADEMIC AND PRACTICAL
7 CURRICULUM APPROVED BY THE BOARD THAT INCLUDES THE CURRENT
8 GUIDELINES AND RECOMMENDATIONS OF THE CENTERS FOR DISEASE
9 CONTROL AND PREVENTION IN THE PUBLIC HEALTH SERVICE OF THE
10 UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE
11 AMERICAN COUNCIL ON PHARMACEUTICAL EDUCATION OR A SIMILAR
12 HEALTH AUTHORITY OR PROFESSIONAL BODY AND INCLUDES, BUT IS
13 NOT LIMITED TO, DISEASE EPIDEMIOLOGY, VACCINE
14 CHARACTERISTICS, INJECTION TECHNIQUE, EMERGENCY RESPONSE TO
15 ADVERSE EVENTS AND RELATED TOPICS.

16 (2) MAINTENANCE OF A CURRENT CARDIOPULMONARY
17 RESUSCITATION (CPR) CERTIFICATE ACCEPTABLE TO THE BOARD.

18 (3) THAT THE ADMINISTRATION OF INJECTABLE MEDICATIONS,
19 BIOLOGICALS AND IMMUNIZATIONS BE IN ACCORDANCE WITH A
20 DEFINITIVE SET OF TREATMENT GUIDELINES ESTABLISHED BY A
21 PHYSICIAN AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION,
22 ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES GUIDELINES OR
23 ANOTHER COMPETENT AUTHORITY APPROVED BY THE BOARD.

24 (4) THAT A MINIMUM OF TWO HOURS OF THE 30-HOUR
25 REQUIREMENT FOR CONTINUING EDUCATION FOR LICENSE RENEWAL BE
26 DEDICATED TO ADMINISTERING INJECTABLE MEDICATIONS,
27 BIOLOGICALS AND IMMUNIZATIONS.

28 (5) FOR INDIVIDUALS UNDER 18 YEARS OF AGE, THAT PARENTAL
29 CONSENT BE OBTAINED PRIOR TO ADMINISTRATION.

30 (6) MAINTENANCE OF A LEVEL OF PROFESSIONAL LIABILITY

1 INSURANCE COVERAGE IN THE MINIMUM AMOUNT OF \$1,000,000 PER
2 OCCURRENCE OR CLAIMS MADE. FAILURE TO MAINTAIN INSURANCE
3 COVERAGE AS REQUIRED SHALL SUBJECT THE LICENSEES TO
4 DISCIPLINARY PROCEEDINGS. THE BOARD SHALL ACCEPT AS
5 SATISFACTORY EVIDENCE OF INSURANCE COVERAGE ANY OF THE
6 FOLLOWING:

7 (I) PERSONALLY PURCHASED LIABILITY INSURANCE;

8 (II) PROFESSIONAL LIABILITY INSURANCE COVERAGE
9 PROVIDED BY THE INDIVIDUAL LICENSEE'S EMPLOYER; OR

10 (III) SIMILAR INSURANCE COVERAGE ACCEPTABLE TO THE
11 BOARD.

12 (7) NOTIFICATION OF THE INDIVIDUAL'S PRIMARY CARE
13 PROVIDER, IF KNOWN, WITHIN 48 HOURS OF ADMINISTRATION.

14 (B) NO DELEGATION.--EXCEPT AS PROVIDED UNDER SUBSECTION (E),
15 A PHARMACIST'S AUTHORITY TO ADMINISTER INJECTABLE MEDICATIONS,
16 BIOLOGICALS AND IMMUNIZATIONS SHALL NOT BE DELEGATED TO ANY
17 OTHER INDIVIDUAL. A PHARMACY INTERN WHO HAS COMPLETED A COURSE
18 OF EDUCATION AND TRAINING WHICH MEETS THE REQUIREMENTS OF
19 SUBSECTION (A) (1) AND (2) AND MAINTAINS LIABILITY INSURANCE IN
20 THE AMOUNTS SPECIFIED UNDER SUBSECTION (A) (6), MAY ADMINISTER
21 INJECTABLE MEDICATIONS, BIOLOGICALS AND IMMUNIZATIONS, IN
22 KEEPING WITH THE REQUIREMENTS UNDER SUBSECTION (A) (3), TO
23 INDIVIDUALS WHO ARE EIGHT YEARS OF AGE OR OLDER AND INFLUENZA
24 AND COVID-19 IMMUNIZATIONS BY INJECTABLE OR NEEDLE-FREE DELIVERY
25 METHODS TO INDIVIDUALS FIVE YEARS OF AGE OR OLDER ONLY UNDER THE
26 DIRECT, IMMEDIATE AND PERSONAL SUPERVISION OF A PHARMACIST
27 HOLDING THE AUTHORITY TO ADMINISTER INJECTABLE MEDICATIONS,
28 BIOLOGICALS AND IMMUNIZATIONS OR A PHYSICIAN, PHYSICIAN
29 ASSISTANT OR CERTIFIED REGISTERED NURSE PRACTITIONER.

30 (C) REPORT OF ADMINISTRATION.--A SUPERVISING PHARMACIST

1 SHALL REPORT THE ADMINISTRATION OF IMMUNIZATIONS UNDER THIS
2 SECTION TO THE IMMUNIZATION REGISTRY MAINTAINED BY THE
3 DEPARTMENT OF HEALTH WITHIN 72 HOURS OF IMMUNIZATION
4 ADMINISTRATION AND TO THE INDIVIDUAL'S PRIMARY CARE PROVIDER IN
5 ACCORDANCE WITH SUBSECTION (A) (7). NOTHING IN THIS SUBSECTION
6 SHALL BE CONSTRUED TO PROHIBIT A SUPERVISING PHARMACIST FROM
7 DELEGATING THE REPORTING OF IMMUNIZATION ADMINISTRATION TO A
8 PHARMACY INTERN OR TECHNICIAN.

9 (D) INFORMATION AND REFERRAL.--A PHARMACIST, PHARMACY INTERN
10 OR PHARMACIST TECHNICIAN WHO ADMINISTERS AN INFLUENZA OR COVID-
11 19 IMMUNIZATION TO AN INDIVIDUAL UNDER 18 YEARS OF AGE SHALL
12 INFORM THE PARENT OR ADULT CAREGIVER OF THE IMPORTANCE OF A
13 WELL-CHILD VISIT WITH A PEDIATRICIAN OR OTHER LICENSED PRIMARY
14 CARE PROVIDER AND REFER THE PATIENT AS APPROPRIATE.

15 (E) DELEGATION OF AUTHORITY.--A PHARMACIST WHO HOLDS THE
16 AUTHORITY TO ADMINISTER INJECTABLE MEDICATIONS, BIOLOGICALS AND
17 IMMUNIZATIONS MAY DELEGATE THE AUTHORITY TO ADMINISTER:

18 (1) INFLUENZA AND COVID-19 IMMUNIZATIONS TO A CERTIFIED
19 REGISTERED NURSE PRACTITIONER, PHYSICIAN ASSISTANT,
20 REGISTERED NURSE OR LICENSED PRACTICAL NURSE; OR

21 (2) COVID-19 IMMUNIZATIONS THAT ARE AUTHORIZED OR THAT
22 ARE LICENSED BY THE UNITED STATES FOOD AND DRUG
23 ADMINISTRATION TO INDIVIDUALS 13 YEARS OF AGE OR OLDER OR
24 INFLUENZA VACCINATIONS THAT ARE RECOMMENDED BY THE ADVISORY
25 COMMITTEE ON IMMUNIZATION PRACTICES TO INDIVIDUALS 13 YEARS
26 OF AGE OR OLDER TO A PHARMACY TECHNICIAN IF:

27 (I) THE PHARMACY TECHNICIAN:

28 (A) UNTIL THE BOARD PROMULGATES FINAL
29 REGULATIONS IMPLEMENTING REGISTRATION OF PHARMACY
30 TECHNICIANS, HOLDS A NATIONAL CERTIFICATION FROM THE

1 PHARMACY TECHNICIAN CERTIFICATION BOARD OR THE
2 NATIONAL HEALTHCAREER ASSOCIATION; OR

3 (B) AFTER THE BOARD PROMULGATES FINAL
4 REGULATIONS IMPLEMENTING REGISTRATION OF PHARMACY
5 TECHNICIANS, IS REGISTERED WITH THE BOARD.

6 (II) THE FOLLOWING CONDITIONS ARE MET:

7 (A) THE SUPERVISING QUALIFIED PHARMACIST IS
8 PROVIDING DIRECT, IMMEDIATE AND PERSONAL SUPERVISION
9 TO THE QUALIFIED PHARMACY TECHNICIAN WHO IS
10 ADMINISTERING THE IMMUNIZATIONS OR VACCINATIONS.

11 (B) THE QUALIFIED PHARMACY TECHNICIAN HAS
12 COMPLETED A PRACTICAL TRAINING PROGRAM THAT IS
13 APPROVED BY THE ACCREDITATION COUNCIL FOR PHARMACY
14 EDUCATION AND THAT INCLUDES HANDS-ON INJECTION
15 TECHNIQUE AND THE RECOGNITION AND TREATMENT OF
16 EMERGENCY REACTIONS TO VACCINES.

17 (C) THE QUALIFIED PHARMACY TECHNICIAN HAS A
18 CURRENT CERTIFICATE IN BASIC CARDIOPULMONARY
19 RESUSCITATION.

20 (D) THE QUALIFIED PHARMACY TECHNICIAN HAS
21 OBTAINED LIABILITY INSURANCE AS REQUIRED UNDER
22 SUBSECTION (A) (6) THROUGH THE QUALIFIED PHARMACY
23 TECHNICIAN'S EMPLOYER.

24 (E) ADMINISTRATION OF A COVID-19 IMMUNIZATION OR
25 INFLUENZA VACCINATIONS SHALL BE IN KEEPING WITH THE
26 REQUIREMENTS UNDER SUBSECTION (A) (3).

27 SECTION 1003. CLINICAL LABORATORY CERTIFICATE.

28 (A) CERTIFICATE.--IF A PHARMACY HOLDS A VALID CERTIFICATE OF
29 WAIVER ISSUED BY THE CENTERS FOR MEDICARE AND MEDICAID SERVICES,
30 A PHARMACY OR PHARMACIST MAY ORDER AND PERFORM LABORATORY

1 EXAMINATIONS AND PROCEDURES FOR COVID-19, INFLUENZA, RESPIRATORY
2 SYNCYTIAL VIRUS AND STREPTOCOCCAL INFECTIONS AUTHORIZED OR
3 APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION UNDER
4 THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988 (PUBLIC
5 LAW 100-578, 102 STAT. 2903) AND SHALL BE EXEMPT FROM THE
6 REQUIREMENTS UNDER SECTION 3 OF THE ACT OF SEPTEMBER 26, 1951
7 (P.L.1539, NO.389), KNOWN AS THE CLINICAL LABORATORY ACT.

8 (B) DESIGNATION.--A PHARMACIST MAY DESIGNATE THE
9 ADMINISTRATION OF A TEST UNDER SUBSECTION (A) TO A PHARMACY
10 INTERN OR PHARMACY TECHNICIAN IF THE DESIGNATION BY THE
11 PHARMACIST TO A PHARMACY INTERN OR PHARMACY TECHNICIAN AND THE
12 ADMINISTRATION OF THE TEST IS IN KEEPING WITH NATIONALLY
13 RECOGNIZED CLINICAL PRACTICE GUIDELINES THAT HAVE NOT BEEN
14 DISAPPROVED BY THE DEPARTMENT OF HEALTH THROUGH TRANSMISSION TO
15 THE LEGISLATIVE REFERENCE BUREAU FOR PUBLICATION IN THE NEXT
16 AVAILABLE ISSUE OF THE PENNSYLVANIA BULLETIN.
17 SECTION 1004. REPORT ON PHARMACY-ADMINISTERED VACCINES.

18 (A) REPORT.--THE DEPARTMENT OF HEALTH SHALL, IN CONSULTATION
19 WITH THE BOARD, REPORT TO THE PRESIDENT PRO TEMPORE OF THE
20 SENATE, THE MAJORITY LEADER AND THE MINORITY LEADER OF THE
21 SENATE, THE SPEAKER OF THE HOUSE OF REPRESENTATIVES AND THE
22 MAJORITY LEADER AND THE MINORITY LEADER OF THE HOUSE OF
23 REPRESENTATIVES INFORMATION CONCERNING PHARMACIST ACTIVITIES
24 AUTHORIZED UNDER THIS CHAPTER, INCLUDING:

25 (1) THE NUMBER OF INJECTABLE MEDICATIONS, BIOLOGICALS
26 AND IMMUNIZATIONS ADMINISTERED TO INDIVIDUALS UNDER 18 YEARS
27 OF AGE BROKEN DOWN BY AGE.

28 (2) THE NUMBER OF INJECTABLE MEDICATIONS, BIOLOGICALS
29 AND IMMUNIZATIONS ADMINISTERED TO INDIVIDUALS UNDER 18 YEARS
30 OF AGE BROKEN DOWN BY TYPE OF INJECTABLE MEDICATIONS,

1 BIOLOGICALS AND IMMUNIZATIONS.

2 (3) SUBJECT TO INFORMATION BEING MADE AVAILABLE, AN
3 ASSESSMENT ON WHETHER THERE IS A CHANGE IN THE NUMBER OF WELL
4 VISITS FOR CHILDREN WITH THEIR PRIMARY PEDIATRIC CARE
5 PROVIDER ATTRIBUTABLE PHARMACIST SERVICES AUTHORIZED UNDER
6 THIS CHAPTER.

7 (4) BEGINNING FROM THE EFFECTIVE DATE OF THIS SECTION,
8 CHANGES IN THE PHARMACY IMMUNIZATION RATES FOR INDIVIDUALS
9 UNDER 18 YEARS OF AGE.

10 (B) SCOPE OF REPORT.--THE DEPARTMENT OF HEALTH SHALL REVIEW
11 DATA AVAILABLE FOR INJECTABLE MEDICATIONS, BIOLOGICALS AND
12 IMMUNIZATIONS ADMINISTERED BY A PHARMACIST, PHARMACY INTERN OR
13 TECHNICIAN IN THIS COMMONWEALTH. THE DEPARTMENT OF HEALTH SHALL
14 ALSO REVIEW DATA AVAILABLE FROM OTHER STATE GOVERNMENTS WHICH
15 HAVE AUTHORIZED PHARMACISTS TO PROVIDE SIMILAR PHARMACY SERVICES
16 AS AUTHORIZED UNDER THIS CHAPTER.

17 (C) TIMING OF REPORT.--THE DEPARTMENT OF HEALTH SHALL REPORT
18 ITS FINDINGS NO LATER THAN FIVE YEARS FOLLOWING THE EFFECTIVE
19 DATE OF THIS SUBSECTION AND INCLUDE RECOMMENDATIONS FOR CHANGES
20 IN THE LAWS OF THIS COMMONWEALTH.

21 (D) PUBLICATION.--UPON COMPLETION OF THE REPORT AND
22 TRANSMISSION OF THE REPORT UNDER SUBSECTION (A), THE DEPARTMENT
23 OF HEALTH SHALL PUBLISH THE FINDINGS ON THE DEPARTMENT OF
24 HEALTH'S PUBLICLY ACCESSIBLE INTERNET WEBSITE.

25 SECTION 12. REPEALS ARE AS FOLLOWS:

26 (1) THE GENERAL ASSEMBLY DECLARES THAT THE REPEAL UNDER
27 PARAGRAPH (2) IS NECESSARY TO EFFECTUATE THE ADDITION OF
28 SECTION 1002 OF THE ACT.

29 (2) SECTIONS 9.2 AND 9.5 OF THE ACT OF SEPTEMBER 27,
30 1961 (P.L.1700, NO.699), KNOWN AS THE PHARMACY ACT, ARE

1 REPEALED.

2 SECTION 13. THE ADDITION OF SECTION 1002 OF THE ACT IS A
3 CONTINUATION OF SECTIONS 9.2 AND 9.5 OF THE ACT OF SEPTEMBER 27,
4 1961 (P.L.1700, NO.699), KNOWN AS THE PHARMACY ACT. EXCEPT AS
5 OTHERWISE PROVIDED IN SECTION 1002 OF THE ACT, ALL ACTIVITIES
6 INITIATED UNDER SECTIONS 9.2 AND 9.5 OF THE PHARMACY ACT SHALL
7 CONTINUE AND REMAIN IN FULL FORCE AND EFFECT AND MAY BE
8 COMPLETED UNDER SECTION 1002 OF THE ACT. ORDERS, REGULATIONS,
9 RULES AND DECISIONS WHICH WERE MADE UNDER SECTIONS 9.2 AND 9.5
10 OF THE PHARMACY ACT AND WHICH ARE IN EFFECT ON THE EFFECTIVE
11 DATE OF SECTION 12(2) OF THIS ACT SHALL REMAIN IN FULL FORCE AND
12 EFFECT UNTIL REVOKED, VACATED OR MODIFIED UNDER SECTION 1002 OF
13 THE ACT. CONTRACTS, OBLIGATIONS AND COLLECTIVE BARGAINING
14 AGREEMENTS ENTERED INTO UNDER SECTIONS 9.2 AND 9.5 OF THE
15 PHARMACY ACT ARE NOT AFFECTED NOR IMPAIRED BY THE REPEAL OF
16 SECTIONS 9.2 AND 9.5 OF THE PHARMACY ACT.

17 SECTION 14. THE FOLLOWING SHALL APPLY:

18 (1) THE ADDITION OF CHAPTER 6 AND SECTION 703.1 OF THE
19 ACT SHALL APPLY TO A CONTRACT ISSUED, RENEWED OR AMENDED
20 AFTER THE EFFECTIVE DATE OF THIS SECTION.

21 (2) THE FOLLOWING SHALL APPLY:

22 (I) FOR A HEALTH INSURANCE POLICY FOR WHICH EITHER
23 RATES OR FORMS ARE REQUIRED TO BE FILED WITH THE FEDERAL
24 GOVERNMENT OR THE INSURANCE DEPARTMENT, THIS ACT SHALL
25 APPLY TO THE HEALTH INSURANCE POLICY FOR WHICH A FORM OR
26 RATE IS FIRST APPROVED ON OR AFTER THE EFFECTIVE DATE OF
27 THIS PARAGRAPH.

28 (II) FOR A HEALTH INSURANCE POLICY FOR WHICH NEITHER
29 RATES NOR FORMS ARE REQUIRED TO BE FILED WITH THE FEDERAL
30 GOVERNMENT OR THE INSURANCE DEPARTMENT, THIS ACT SHALL

1 APPLY TO THE HEALTH INSURANCE POLICY ISSUED OR RENEWED ON
2 OR AFTER 180 DAYS AFTER THE EFFECTIVE DATE OF THIS
3 PARAGRAPH.

4 SECTION 15. THIS ACT SHALL TAKE EFFECT AS FOLLOWS:

5 ~~(1) SECTION 14 OF THIS ACT SHALL TAKE EFFECT IN 90 DAYS. <--~~

6 (1) THE FOLLOWING PROVISIONS SHALL TAKE EFFECT IN 90 <--
7 DAYS:

8 (I) THE AMENDMENT OR ADDITION OF THE DEFINITIONS OF
9 "AFFILIATE" OR "AFFILIATED," "COMPLEX OR CHRONIC MEDICAL
10 CONDITION," "COVERED ENTITY," "ERISA," "HEALTH BENEFIT
11 PLAN," "HEALTH INSURANCE POLICY," "HEALTH INSURER
12 CLIENT," "LICENSEE OR REGISTRANT," "MAIL ORDER PHARMACY,"
13 "MAINTENANCE MEDICATION," "RARE MEDICAL CONDITION,"
14 "RETAIL PHARMACY," "SPECIALTY DRUG," "SPECIALTY PHARMACY"
15 AND "SPREAD PRICING."

16 (II) SECTION 14 OF THIS ACT.

17 (2) THIS SECTION SHALL TAKE EFFECT IMMEDIATELY.

18 (3) THE REMAINDER OF THIS ACT SHALL TAKE EFFECT IN 120
19 DAYS.